159 related articles for article (PubMed ID: 38393414)
21. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
[TBL] [Abstract][Full Text] [Related]
22. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
24. Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.
Rucinski A; Brons S; Richter D; Habl G; Debus J; Bert C; Haberer T; Jäkel O
Radiat Oncol; 2015 Feb; 10():56. PubMed ID: 25886457
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
26. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall.
Fischer-Valuck BW; Chundury A; Gay H; Bosch W; Michalski J
Pract Radiat Oncol; 2017; 7(3):195-202. PubMed ID: 28089528
[TBL] [Abstract][Full Text] [Related]
27. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronic acid spacer in focal prostate reirradiation: A single centre experience.
Ozyigit G; Hurmuz P; Akinci D; Esen SCB; Yilmaz MT; Akdogan B; Akyol FH
Cancer Radiother; 2020 Dec; 24(8):805-811. PubMed ID: 32565071
[TBL] [Abstract][Full Text] [Related]
29. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.
Mahal BA; Ziehr DR; Hyatt AS; Neubauer-Sugar EH; O'Farrell DA; O'Leary MP; Steele GS; Niedermayr TR; Beard CJ; Martin NE; Orio PF; D'Amico AV; Devlin PM; Nguyen PL
Brachytherapy; 2014; 13(5):442-9. PubMed ID: 24880584
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
Hwang ME; Mayeda M; Shaish H; Elliston CD; Spina CS; Wenske S; Deutsch I
Br J Radiol; 2021 Mar; 94(1119):20200433. PubMed ID: 33586999
[TBL] [Abstract][Full Text] [Related]
31. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
[TBL] [Abstract][Full Text] [Related]
32. Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer.
Ahmad Khalil D; Jazmati D; Geismar D; Wulff J; Bäumer C; Kramer PH; Steinmeier T; Schulze Schleitthoff S; Plaude S; Bischoff M; Tschirdewahn S; Hadaschik B; Timmermann B
Radiat Oncol; 2022 Apr; 17(1):64. PubMed ID: 35365170
[TBL] [Abstract][Full Text] [Related]
33. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
Hamstra DA; Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Daignault-Newton S; Fischer-Valuck BW; Chundury A; Gay H; Bosch W; Michalski J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):976-985. PubMed ID: 28209443
[TBL] [Abstract][Full Text] [Related]
34. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
35. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Miller LE; Efstathiou JA; Bhattacharyya SK; Payne HA; Woodward E; Pinkawa M
JAMA Netw Open; 2020 Jun; 3(6):e208221. PubMed ID: 32585020
[TBL] [Abstract][Full Text] [Related]
36. An optimal method of hydrogel spacer insertion for stereotactic body radiation therapy of prostate cancer.
Kobayashi H; Eriguchi T; Tanaka T; Ogata T; Osaki N; Suzuki H; Kosugi M; Kumabe A; Sato K; Ishida M
Jpn J Radiol; 2024 Apr; 42(4):406-414. PubMed ID: 37932639
[TBL] [Abstract][Full Text] [Related]
37. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
38. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
40. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes.
Song DY; Herfarth KK; Uhl M; Eble MJ; Pinkawa M; van Triest B; Kalisvaart R; Weber DC; Miralbell R; Deweese TL; Ford EC
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):81-7. PubMed ID: 23414766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
